Ouro Medicines is dedicated to developing immune reset therapeutics for people living with chronic immune-mediated diseases. Our approach is focused on leveraging T cell engagers in B cell mediated diseases to achieve immune resets that enable durable remissions without ongoing immunosuppression for patients. Based in San Francisco, Ouro was founded by Monograph Capital in partnership with GSK. We are also backed by leading investors TPG, NEA, Norwest and more.
Company Details
- Employees
- 16
- Founded
- -
- Address
- San Francisco, Ca, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.ouromedicines.com
- HQ
- San Francisco, CA
Ouro Medicines Questions
Ouro Medicines's website is http://www.ouromedicines.com
Ouro Medicines's LinkedIn profile is https://www.linkedin.com/company/ouromedicines
Ouro Medicines has
16 employees.
View email and phone details for 16
employees at Ouro Medicines.
Ouro Medicines's industry is
Biotechnology Research
Ouro Medicines's top competitors are
Verdiva Bio,
Tenvie Therapeutics,
Windward Bio,
Be Biopharma,
Timberlyne Therapeutics,
Umoja Biopharma,
Kardigan,
Normunity,
Tune Therapeutics,
Light Horse Therapeutics.
Ouro Medicines's categories are Biotechnology Research
Ouro Medicines's founding year is 2024
